/VKTX
VKTX Stock - Viking Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$35.19+3.65%
+$1.24 (+3.65%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.70
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.94
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+198.4%upside
Target: $105.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VKTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$34.84 – $35.54
TARGET (TP)$105.00
STOP LOSS$32.37
RISK/REWARD1:24.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.64
52W High$43.55
52W Low$18.92
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-150,921,000 | $-100,827,000 | $-70,355,000 | $-55,682,000 | $-42,662,000 |
| Net Income | $-109,963,000 | $-85,895,000 | $-68,867,000 | $-54,990,000 | $-39,495,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.01 | $-0.91 | $-0.88 | $-0.70 | $-0.50 |
Company Overview
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
1
8%
Buy / Outperform
10
77%
Hold / Neutral
2
15%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
11 Bullish2 Neutral/Bearish
Price Targets
$83
Average Target
↑ 137.1% Upside
Now
$22
Low
$83
Average
$138
High
Based on 16 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 29th 2025 | Canaccord Genuity | Initiation | Buy | $106 |
| April 29th 2025 | Cantor Fitzgerald | Initiation | Overweight | $104 |
| April 8th 2025 | Goldman | Initiation | Neutral | $30 |
| February 13th 2025 | Scotiabank | Initiation | Sector Outperform | $102 |
| February 7th 2025 | Citigroup | Initiation | Neutral | $38 |
| December 2nd 2024 | Piper Sandler | Initiation | Overweight | - |
| November 22nd 2024 | B. Riley Securities | Initiation | Buy | $109 |
| November 4th 2024 | H.C. Wainwright | Reiterated | Buy | $102← $90 |
| September 11th 2024 | JP Morgan | Initiation | Overweight | $80 |
| June 27th 2024 | Morgan Stanley | Initiation | Overweight | $105 |
| May 16th 2024 | Raymond James | Upgrade | Strong Buy | $116← $115 |
| March 26th 2024 | Oppenheimer | Reiterated | Outperform | $138← $116 |
| March 7th 2024 | Jefferies | Initiation | Buy | $110 |
| February 28th 2024 | Oppenheimer | Reiterated | Outperform | $116← $46 |
| May 31st 2023 | ROTH MKM | Resumed | Buy | $32 |
Earnings History & Surprises
VKTXBeat Rate
39%
Last 18 quarters
Avg Surprise
-2.0%
EPS vs Estimate
Beats / Misses
7/10
1 met exactly
Latest EPS
$-0.81
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.25vs$-0.25
Q2 24
+3.7%
$-0.26vs$-0.27
Q3 24
+23.1%
$-0.20vs$-0.26
Q4 24
+8.3%
$-0.22vs$-0.24
Q1 25
-14.3%
$-0.32vs$-0.28
Q2 25
-20.6%
$-0.41vs$-0.34
Q3 25
-31.8%
$-0.58vs$-0.44
Q4 25
-15.7%
$-0.81vs$-0.70
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 21, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $-0.89 | — | — | — |
Q4 2025 | Oct 22, 2025 | $-0.70 | $-0.81 | -15.7% | ✗ MISS |
Q3 2025 | Jul 23, 2025 | $-0.44 | $-0.58 | -31.8% | ✗ MISS |
Q2 2025 | Apr 23, 2025 | $-0.34 | $-0.41 | -20.6% | ✗ MISS |
Q1 2025 | Feb 5, 2025 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q4 2024 | Oct 23, 2024 | $-0.24 | $-0.22 | +8.3% | ✓ BEAT |
Q3 2024 | Jul 24, 2024 | $-0.26 | $-0.20 | +23.1% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $-0.27 | $-0.26 | +3.7% | ✓ BEAT |
Q1 2024 | Feb 7, 2024 | $-0.25 | $-0.25 | 0.0% | = MET |
Q4 2023 | Oct 25, 2023 | $-0.22 | $-0.23 | -4.5% | ✗ MISS |
Q3 2023 | Jul 26, 2023 | $-0.21 | $-0.19 | +9.5% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $-0.24 | $-0.25 | -4.2% | ✗ MISS |
Q1 2023 | Feb 8, 2023 | $-0.23 | $-0.26 | -13.0% | ✗ MISS |
Q4 2022 | Oct 26, 2022 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q3 2022 | Jul 27, 2022 | $-0.21 | $-0.23 | -9.5% | ✗ MISS |
Q2 2022 | Apr 27, 2022 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q1 2022 | Feb 9, 2022 | $-0.19 | $-0.16 | +15.8% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-0.21 | $-0.17 | +19.0% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $-0.19 | $-0.20 | -5.3% | ✗ MISS |
Latest News
Viking Therapeutics Completes Enrollment Ahead Of Schedule In Phase 3 VANQUISH-1 Trial Evaluating Subcutaneous VK2735 For Obesity
📈 PositiveBenzinga•Nov 19, 2025, 08:23 AM
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $107
📈 PositiveBenzinga•Nov 12, 2025, 01:09 PM•Also:
Viking Therapeutics Data From Phase 2 VENTURE Clinical Study Of VK2735 Demonstrated Improvement In Cardiometabolic Parameters In Participants, Reductions In Prevalence Of Prediabetes And MetS At Week 13
📈 PositiveBenzinga•Nov 6, 2025, 12:25 PM
Viking Therapeutics Announces That Its VV2735 Obesity Program Will Be Featured In Two Poster Presentations At ObesityWeek 2025 In Atlanta
📈 PositiveBenzinga•Oct 29, 2025, 08:23 PM
Canaccord Genuity Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $106
📈 PositiveBenzinga•Oct 29, 2025, 11:07 AM•Also:
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $75
➖ NeutralBenzinga•Oct 24, 2025, 01:27 PM•Also:
Morgan Stanley Maintains Overweight on Viking Therapeutics, Raises Price Target to $102
📈 PositiveBenzinga•Oct 23, 2025, 01:14 PM
Viking Therapeutics Q3 EPS $(0.81) Misses $(0.72) Estimate
📉 NegativeBenzinga•Oct 22, 2025, 08:11 PM
Viking Therapeutics Initiates VK2735 Maintenance Dosing Clinical Trial In Obesity Patients
📈 PositiveBenzinga•Oct 21, 2025, 11:07 AM
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero
📈 PositiveSeeking Alpha•Oct 9, 2025, 03:33 PM•Also: , ,
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
📈 PositiveBenzinga•Sep 29, 2025, 02:38 PM
BTIG Reiterates Buy on Viking Therapeutics, Maintains $125 Price Target
📈 PositiveBenzinga•Sep 22, 2025, 02:26 PM
FDA Launches Green List To Protect Americans From Illegal Imported GLP-1 Drug Ingredients
➖ NeutralBenzinga•Sep 5, 2025, 03:40 PM•Also: , ,
Viking Therapeutics shares are trading lower following updates from the company's Phase 2 trial for its obesity drug.
📉 NegativeBenzinga•Aug 19, 2025, 03:46 PM
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
📈 PositiveBenzinga•Aug 19, 2025, 03:22 PM
Top 10 Trending Stocks On WallStreetBets As Of Aug. 19, 2025 (Via Swaggy Stocks)
➖ NeutralBenzinga•Aug 19, 2025, 01:19 PM•Also: , ,
Viking Therapeutics plunges after mid-stage trial data for oral weight loss drug
📉 NegativeSeeking Alpha•Aug 19, 2025, 11:56 AM
VKTX stock has given up its prior gain. Viking Therapeutics shares were trading higher after the company's obesity drug showed up to 12% weight loss in a Phase 2 trial.
➖ NeutralBenzinga•Aug 19, 2025, 11:46 AM
Market-Moving News for August 19th
➖ NeutralBenzinga•Aug 19, 2025, 11:23 AM•Also: ,
Viking Therapeutics shares are trading higher after the company's obesity drug showed up to 12% weight loss in a Phase 2 trial.
📈 PositiveBenzinga•Aug 19, 2025, 11:16 AM
Frequently Asked Questions about VKTX
What is VKTX's current stock price?
Viking Therapeutics, Inc. (VKTX) is currently trading at $35.19 per share. The stock has moved +3.65% today.
What is the analyst price target for VKTX?
The average analyst price target for VKTX is $105.00, based on 1 analyst.
What sector is Viking Therapeutics, Inc. in?
Viking Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VKTX's market cap?
Viking Therapeutics, Inc. has a market capitalization of $3.98 billion, making it a mid-cap company.
Does VKTX pay dividends?
No, Viking Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
ACAD
ACADIA Pharmaceuticals Inc.
$27.16
Mkt Cap: $4.6B
AKRO
Akero Therapeutics, Inc.
$54.65
Mkt Cap: $4.5B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
IMVT
Immunovant, Inc.
$26.68
Mkt Cap: $4.7B
KYMR
Kymera Therapeutics, Inc.
$83.99
Mkt Cap: $6.0B
LGND
Ligand Pharmaceuticals Incorporated
$200.33
Mkt Cap: $3.9B
NAMS
NewAmsterdam Pharma Company N.V.
$35.11
Mkt Cap: $4.0B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
Explore stocks similar to VKTX for comparison